Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

WalkMe: Q3 Earnings Insights

WalkMe (NASDAQ:WKME) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM. Here’s what investors…
byBenzinga Insights
November 14, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

WalkMe (NASDAQ:WKME) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.

Here’s what investors need to know about the announcement.

Earnings

WalkMe beat estimated earnings by 500.0%, reporting an EPS of $0.04 versus an estimate of $-0.01.

Revenue was up $3.66 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.07 which was followed by a 1.54% increase in the share price the next day.

Here’s a look at WalkMe’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.07 -0.11 -0.14 -0.19
EPS Actual 0 -0.08 -0.10 -0.14
Revenue Estimate 65.70M 65.05M 63.98M 62.97M
Revenue Actual 66.16M 65.89M 64.86M 63.35M

To track all earnings releases for WalkMe visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aurora Touts 41% YoY Increase In International Medical Cannabis Q3 Revenue, Expands In Australia Via New Acquisition

By Jelena Martinovic
February 8, 12:04 PM
Canadian medical cannabis company Aurora Cannabis reported its financial and operational results for Q3 2024. Net revenue increased to CAD64.4m ($42m), up from CAD61.1m in the same quarter the previous year. Medical cannabis net revenue rose by 16% to CAD45.1m, representing 70% of Aurora's consolidated net revenue. Gross profit reached CAD19.8m, up from CAD3.7m in Q3 2022, with adjusted gross profit before fair value adjustments increasing to CAD32.4m from CAD28m. The company recorded a CAD25.5m net loss compared to CAD67.2m in the same quarter in the previous year. Adjusted EBITDA came in at CAD4.3m, up from CAD3m. Miguel Martin, CEO of Aurora, said the company's international medical net revenue had seen year-on-year growth of 41%.

ACB